Chien Chun-Ru, Chen Hung-Jen
Department of Radiation Oncology, China Medical University Hospital, Taichung, Taiwan;; School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan.
Division of Pulmonary and Critical Care Medicine, China Medical University Hospital, Taichung, Taiwan;; Department of Respiratory Therapy, China Medical University, Taichung, Taiwan.
J Thorac Dis. 2016 Nov;8(11):E1455-E1461. doi: 10.21037/jtd.2016.11.110.
Novel targeted therapy for patients with non-small-cell lung cancer (NSCLC) and oncogenic mutations along with poor performance status (PS) sometimes evokes a "Lazarus" response. Moreover, for critically ill patients with NSCLC and respiratory failure requiring mechanical ventilation (MV) in the intensive care unit (ICU), only a few case reports have demonstrated positive outcomes with targeted therapy. This perspective review describes in detail the most recently published data in order to highlight the findings and the main pitfalls of targeted therapy for patients with NSCLC in the ICU.
针对非小细胞肺癌（NSCLC）且伴有致癌突变以及身体状况较差（PS）的患者，新型靶向治疗有时会引发“拉撒路”反应。此外，对于重症监护病房（ICU）中需要机械通气（MV）的非小细胞肺癌合并呼吸衰竭的危重症患者，仅有少数病例报告显示靶向治疗取得了积极效果。这篇观点性综述详细描述了最新发表的数据，以突出ICU中非小细胞肺癌患者靶向治疗的研究结果和主要缺陷。
